

Consensus Formed on Eosinophilic Esophagitis

BY DIANA MAHONEY
New England Bureau

In the absence of pathologic gastroesophageal reflux disease, young children with esophageal symptoms or feeding problems and older children and adults with dysphagia or esophageal food impaction should be evaluated for eosinophilic esophagitis, particularly if their symptoms are unresponsive or only partially responsive to acid blockade, ac-

ording to a new consensus report on the inflammatory gastroesophageal disorder. The report appears in the October 2007 issue of *Gastroenterology*.

Characterized by a range of gastrointestinal symptoms including abdominal pain, nausea, regurgitation, and/or vomiting along with severely elevated levels of eosinophils, eosinophilic esophagitis (EE) is an "enigmatic" disease that is frequently mistaken for gastroesophageal reflux disease (GERD), said Dr. Glenn T. Furuta,

cochair of the First International Gastrointestinal Eosinophilic Research Symposium (FIGERS), from which the consensus report was generated.

Because EE and GERD require different treatment strategies and are associated with different long-term consequences, distinguishing between the two is critical, but doing so has been hindered by the absence of definitive diagnostic and treatment guidelines for EE, said Dr. Furuta of Children's Hospital of Denver. "The con-

sensus report is the best first step in providing outstanding care to children and adults who are affected by this newly recognized disease," he said in an interview.

Developed through the collaboration of 32 physicians from multiple disciplines, including pediatric and adult gastroenterology, allergy, and pathology, the consensus report is based on a systematic review of data from 80 studies published between 1977 and 2006 including 754 children and 323 adults, as well as expert opinion.

Among the most important features of the report are its diagnostic guidelines, Dr. Furuta said. In this regard, "the report states that affected patients should have symptoms referable to the esophagus that occur in combination with greater than or equal to 15 eosinophils per high-powered field in the esophageal mucosa with normal gastric and duodenal mucosa," he said. "Most importantly, GERD must have been ruled out as a cause of these findings."

The available data on the natural history of the disease suggest that EE is a chronic condition with persistent or relapsing symptoms. "To date, esophageal strictures and small caliber esophagus, often resulting in food impaction, have been the major complications identified," the authors wrote in the report. "When these findings are encountered, either radiologically or at endoscopy, a high index of suspicion should be raised for EE and mucosal biopsies should be obtained."

Importantly, mucosal pinch biopsies are recommended for all patients in whom eosinophilic esophagitis is in the differential diagnosis, regardless of the gross appearance of the mucosa, the authors wrote. Additionally, multiple biopsies should be obtained from different esophageal locations along the length of the esophagus, and they should be obtained from the stomach and duodenum to rule out other gastrointestinal diseases, they stated.

When endoscopy and biopsy do not provide sufficient information to distinguish between GERD and eosinophilic esophagitis, "intraesophageal pH monitoring may be of use in excluding pathologic reflux as either the primary or a concomitant cause for esophageal eosinophilia," according to the report. "Alternatively, an upper endoscopy after 6-8 weeks of high-dose proton pump inhibitor treatment can help determine the etiology of esophageal eosinophilia."

Regarding diagnostic histopathology, based on the available data and the panel's collective clinical experience, "we conclude that a peak count of 15 intraepithelial eosinophils per high-powered field is an absolute minimum number to make the diagnosis of EE in the proper clinical context," they wrote. For research purposes, it may be useful to use a higher threshold of peak eosinophils in order to increase the specificity of the diagnosis, they noted.

Additional histopathologic features that, while not pathognomonic, may be helpful in establishing a diagnosis, are eosinophil microabscesses, surface layering of eosinophils, basal layer hyperplasia, papillary lengthening, degranulating eosinophils, and lamina propria fibrosis and in-

CHANTIX™
(varenicline) TABLETS

INDICATIONS AND USAGE

CHANTIX is indicated as an aid to smoking cessation treatment.

PRECAUTIONS

General Nausea was the most common adverse event associated with CHANTIX treatment. Nausea was generally described as mild or moderate and often transient; however, for some subjects, it was persistent over several months. The incidence of nausea was dose-dependent. Initial dose-titration was beneficial in reducing the occurrence of nausea. Nausea was reported by approximately 30% of patients treated with CHANTIX 1 mg BID after an initial week of dose titration. In patients taking CHANTIX 0.5 mg BID, the incidence of nausea was 16% following initial titration. Approximately 3% of subjects treated with CHANTIX 1 mg BID in studies involving 12 weeks of treatment discontinued treatment prematurely because of nausea. For patients with intolerable nausea, dose reduction should be considered.

Effect of smoking cessation. Physiological changes resulting from smoking cessation, with or without treatment with CHANTIX, may alter the pharmacokinetics or pharmacodynamics of some drugs, for which dosage adjustment may be necessary (examples include theophylline, warfarin and insulin).

Drug Interactions Based on varenicline characteristics and clinical experience to date, CHANTIX has no clinically meaningful pharmacokinetic drug interactions (See Full Prescribing Information, CLINICAL PHARMACOLOGY, Drug-Drug Interactions).

Carcinogenesis, Mutagenesis, Impairment of Fertility Carcinogenesis. Lifetime carcinogenicity studies were performed in CD-1 mice and Sprague-Dawley rats. There was no evidence of a carcinogenic effect in mice administered varenicline by oral gavage for 2 years at doses up to 20 mg/kg/day (47 times the maximum recommended human daily exposure based on AUC). Rats were administered varenicline (1, 5, and 15 mg/kg/day) by oral gavage for 2 years. In male rats (n = 65 per sex per dose group), incidences of fibroma (tumor of the brown fat) were increased at the mid dose (1 tumor, 5 mg/kg/day, 23 times the maximum recommended human daily exposure based on AUC) and maximum dose (2 tumors, 15 mg/kg/day, 67 times the maximum recommended human daily exposure based on AUC). The clinical relevance of this finding to humans has not been established. There was no evidence of carcinogenicity in female rats.

Mutagenesis. Varenicline was not genotoxic, with or without metabolic activation, in the following assays: Ames bacterial mutation assay; mammalian CHO/HGPRT assay; and tests for cytogenetic aberrations *in vivo* in rat bone marrow and *in vitro* in human lymphocytes.

Impairment of fertility. There was no evidence of impairment of fertility in either male or female Sprague-Dawley rats administered varenicline succinate up to 15 mg/kg/day (67 and 36 times, respectively, the maximum recommended human daily exposure based on AUC at 1 mg BID). However, a decrease in fertility was noted in the offspring of pregnant rats who were administered varenicline succinate at an oral dose of 15 mg/kg/day (36 times the maximum recommended human daily exposure based on AUC at 1 mg BID). This decrease in fertility in the offspring of treated female rats was not evident at an oral dose of 3 mg/kg/day (9 times the maximum recommended human daily exposure based on AUC at 1 mg BID).

Pregnancy Pregnancy Category C. Varenicline succinate was not teratogenic in rats and rabbits at oral doses up to 15 and 30 mg/kg/day, respectively (36 and 50-times the maximum recommended human daily exposure based on AUC at 1 mg BID, respectively). **Nonteratogenic effects** Varenicline succinate has been shown to have an adverse effect on the fetus in animal reproduction studies. Administration of varenicline succinate to pregnant rabbits resulted in reduced fetal weights at an oral dose of 30 mg/kg/day (50 times the human AUC at 1 mg BID); this reduction was not evident following treatment with 10 mg/kg/day (23 times the maximum recommended daily human exposure based on AUC). In addition, in the offspring of pregnant rats treated with varenicline succinate there were decreases in fertility and increases in auditory startle response at an oral dose of 15 mg/kg/day (36 times the maximum recommended human daily exposure based on AUC at 1 mg BID). There are no adequate and well-controlled studies in pregnant women. CHANTIX should be used during pregnancy only if the potential benefit justifies the potential risk to the fetus. **Nursing mothers** Although it is not known whether this drug is excreted in human milk, animal studies have demonstrated that varenicline can be transferred to nursing pups. Because many drugs are excreted in human milk and because of the potential for serious adverse reactions in nursing infants from CHANTIX, a decision should be made whether to discontinue nursing or to discontinue the drug, taking into account the importance of the drug to the mother. **Labor and delivery** The potential effects of CHANTIX on labor and delivery are not known. **Pediatric Use** Safety and effectiveness of CHANTIX in pediatric patients have not been established; therefore, CHANTIX is not recommended for use in patients under 18 years of age. **Geriatric Use** A combined single and multiple-dose pharmacokinetic study demonstrated that the pharmacokinetics of 1 mg varenicline given QD or BID to 16 healthy elderly male and female smokers (aged 65-75 yrs) for 7 consecutive days was similar to that of younger subjects. No overall differences in safety or effectiveness were observed between these subjects and younger subjects, and other reported clinical experience has not identified differences in responses between the elderly and younger patients, but greater sensitivity of some older individuals cannot be ruled out. Varenicline is known to be substantially excreted by the kidney, and the risk of toxic reactions to this drug may be greater in patients with impaired renal function. Because elderly patients are more likely to have decreased renal function, care should be taken in dose selection, and it may be useful to monitor renal function (see DOSAGE AND ADMINISTRATION, Special Populations, Patients with Impaired Renal Function). No dosage adjustment is recommended for elderly patients (see DOSAGE AND ADMINISTRATION, Special Populations).

Information for Patients:

- Patients should be instructed to set a date to quit smoking and to initiate CHANTIX treatment one week before the quit date.
- Patients should be advised that CHANTIX should be taken after eating, and with a full glass of water.
- Patients should be instructed how to titrate CHANTIX, beginning at a dose of 0.5 mg/day. Prescribers should explain that one 0.5 mg tablet should be taken daily for the first three days, and that for the next four days, one 0.5 mg tablet should be taken in the morning and one 0.5 mg tablet should be taken in the evening.
- Patients should be advised that, after the first seven days, the dose should be increased to one 1 mg tablet in the morning and one 1 mg tablet in the evening.
- Patients should be encouraged to continue to attempt to quit if they have early lapses after quit day.
- Patients should be informed that nausea and insomnia are side effects of CHANTIX and are usually transient; however, patients should be advised that if they are persistently troubled by these symptoms, they should notify their prescribing physician so that a dose reduction can be considered.
- Patients should also be provided with educational materials and necessary counseling to support an attempt at quitting smoking.
- Patients should be informed that some medications may require dose adjustment after quitting smoking.
- Patients intending to become pregnant or planning to breast-feed an infant should be advised of the risks of smoking and risks and benefits of smoking cessation with CHANTIX.
- Patients should be advised to use caution driving or operating machinery until they know how quitting smoking and/or varenicline may affect them.

ADVERSE REACTIONS

During the premarketing development of CHANTIX, over 4500 individuals were exposed to CHANTIX, with over 450 treated for at least 24 weeks and approximately 100 for a year. Most study participants were treated for 12 weeks or less. In Phase 2 and 3 placebo-controlled studies, the treatment discontinuation rate due to adverse events in patients dosed with 1 mg BID was 12% for CHANTIX compared to 10% for placebo in studies of three months' treatment. In this group, the discontinuation rates for the most common adverse events in CHANTIX treated patients were as follows: nausea (3% vs. 0.5% for placebo), headache (0.6% vs. 0.3% for placebo), insomnia (1.2% vs. 1.1% for placebo), and abnormal dreams (0.3% vs. 0.2% for placebo). Adverse Events were categorized using the Medical Dictionary for Regulatory Activities (MedDRA, Version 7.1).

The most common adverse events associated with CHANTIX (>5% and twice the rate seen in placebo-treated patients) were nausea, sleep disturbance, constipation, flatulence, and vomiting. Smoking cessation, with or without treatment, is associated with nicotine withdrawal symptoms and has also been associated with the exacerbation of underlying psychiatric illness.

The most common adverse event associated with CHANTIX treatment is nausea. For patients treated to the maximum recommended dose of 1 mg BID following initial dosage titration, the incidence of nausea was 30% compared with 10% in patients taking a comparable placebo regimen. In patients taking CHANTIX 0.5 mg BID following initial titration, the incidence was 16% compared with 11% for placebo. Nausea was generally described as mild or moderate and often transient; however, for some subjects, it was persistent throughout the treatment period.

Table 3 shows the adverse events for CHANTIX and Placebo in the 12 week fixed dose studies with titration in the first week (Studies 2 (titrated arm only), 4, and 5). MedDRA High Level Group Terms (HLGT) reported in ≥ 3% of patients in the CHANTIX 1 mg BID dose group, and more commonly than in the placebo group, are listed, along with subordinate Preferred Terms (PT) reported in ≥ 1% of CHANTIX patients (and at least 0.5% more frequent than placebo). Closely related Preferred Terms such as "insomnia", "initial insomnia", "middle insomnia", "Early morning awakening" were grouped, but individual patients reporting two or more grouped events are only counted once.

Table 3: Common Treatment Emergent AEs (%) in the Fixed-Dose, Placebo-Controlled Studies (≥1% in the 1 mg BID CHANTIX Group, and 1 mg BID CHANTIX at least 0.5% more than Placebo)

SYSTEM ORGAN CLASS High Level Group Term Preferred Term	CHANTIX 0.5 mg BID N=129	CHANTIX 1mg BID N=821	Placebo N=805
GASTROINTESTINAL			
GI Signs and Symptoms			
Nausea	16	30	10
Abdominal Pain*	5	7	5
Flatulence	9	6	3
Dyspepsia	5	5	3
Vomiting	1	5	2
GI Motility/Defecation Conditions			
Constipation	5	8	3
Gastroesophageal reflux disease	1	1	0
Salivary Gland Conditions			
Dry mouth	4	6	4



Before prescribing, please consult
Full Prescribing Information.

(Table 3 continued)

PSYCHIATRIC DISORDERS			
Sleep Disorders/Disturbances			
Insomnia**	19	18	13
Abnormal dreams	9	13	5
Sleep disorder	2	5	3
Nightmare	2	1	0
NERVOUS SYSTEM			
Headaches			
Headache	19	15	13
Neurological Disorders NEC			
Dysgeusia	8	5	4
Somnolence	3	3	2
Lethargy	2	1	0
GENERAL DISORDERS			
General Disorders NEC			
Fatigue/Malaise/Asthenia	4	7	6
RESPIRATORY/MEDIAST			
Respiratory Disorders NEC			
Rhinorrhea	0	1	0
Dyspnea	2	1	1
Upper Respiratory Tract Disorder	7	5	4
SKIN/SUBCUTANEOUS TISSUE			
Epidermal and Dermal Conditions			
Rash	1	3	2
Pruritis	0	1	1
METABOLISM & NUTRITION			
Appetite/General Nutrit. Disorders			
Increased appetite	4	3	2
Decreased appetite/Anorexia		2	1

* Includes PTs Abdominal (pain, upper, pain lower, discomfort, tenderness, distension) and Stomach discomfort

** Includes PTs Insomnia/Initial insomnia/Middle insomnia/Early morning awakening

The overall pattern, and the frequency of adverse events during the longer-term trials was very similar to that described in Table 3, though several of the most common events were reported by a greater proportion of patients. Nausea, for instance, was reported in 40% of patients treated with CHANTIX 1 mg BID in a one-year study, compared to 8% of placebo-treated patients.

Following is a list of treatment-emergent adverse events reported by patients treated with CHANTIX during all clinical trials. The listing does not include those events already listed in the previous tables or elsewhere in labeling, those events for which a drug cause was remote, those events which were so general as to be uninformative, and those events reported only once which did not have a substantial probability of being acutely life-threatening. **BLOOD AND LYMPHATIC SYSTEM DISORDERS.** *Infrequent:* Anemia, Lymphadenopathy. *Rare:* Leukocytosis, Thrombocytopenia, Splenomegaly. **CARDIAC DISORDERS.** *Infrequent:* Angina pectoris, Arrhythmia, Bradycardia, Ventricular extrasystoles, Myocardial infarction, Palpitations, Tachycardia. *Rare:* Atrial fibrillation, Cardiac flutter, Coronary artery disease, Cor pulmonale, Acute coronary syndrome. **EAR AND LABYRINTH DISORDERS.** *Infrequent:* Tinnitus, Vertigo. *Rare:* Deafness, Meniere's disease. **ENDOCRINE DISORDERS.** *Infrequent:* Thyroid gland disorders. **EYE DISORDERS.** *Infrequent:* Conjunctivitis, Dry eye, Eye irritation, Vision blurred, Visual disturbance, Eye pain. *Rare:* Acquired night blindness, Blindness transient, Cataract subcapsular, Ocular vascular disorder, Photophobia, Vitreous floaters. **GASTROINTESTINAL DISORDERS.** *Frequent:* Diarrhea, Gingivitis. *Infrequent:* Dysphagia, Enterocolitis, Eructation, Gastritis, Gastrointestinal hemorrhage, Mouth ulceration, Esophagitis. *Rare:* Gastric ulcer, Intestinal obstruction, Pancreatitis acute. **GENERAL DISORDERS AND ADMINISTRATION SITE CONDITIONS.** *Frequent:* Chest pain, Influenza like illness, Edema, Thirst. *Infrequent:* Chest discomfort, Chills, Pyrexia. **HEPATOBIILIARY DISORDERS.** *Infrequent:* Gall bladder disorder. **IMMUNE SYSTEM DISORDERS.** *Infrequent:* Hypersensitivity. *Rare:* Drug hypersensitivity. **INVESTIGATIONS.** *Frequent:* Liver function test abnormal, Weight increased. *Infrequent:* Hypersensitivity. **RESPIRATORY, THORACIC AND MEDIASTINAL DISORDERS.** *Frequent:* Epistaxis, Respiratory disorders. *Infrequent:* Asthma. *Rare:* Pleurisy, Pulmonary embolism. **SKIN AND SUBCUTANEOUS TISSUE DISORDERS.** *Frequent:* Hyperhidrosis. *Infrequent:* Acne, Dermatitis, Dry skin, Eczema, Erythema, Psoriasis, Urticaria. *Rare:* Photosensitivity reaction. **VASCULAR DISORDERS.** *Frequent:* Hot flush, Hypertension. *Infrequent:* Hypotension, Peripheral ischemia, Thrombosis.

DRUG ABUSE AND DEPENDENCE

Controlled Substance Class Varenicline is not a controlled substance. **Humans:** Fewer than 1 out of 1000 patients reported euphoria in clinical trials with CHANTIX. At higher doses (greater than 2 mg), CHANTIX produced more frequent reports of gastrointestinal disturbances such as nausea and vomiting. There is no evidence of dose-escalation to maintain therapeutic effects in clinical studies, which suggests that tolerance does not develop. Abrupt discontinuation of CHANTIX was associated with an increase in irritability and sleep disturbances in up to 3% of patients. This suggests that, in some patients, varenicline may produce mild physical dependence which is not associated with addiction. In a human laboratory abuse liability study, a single oral dose of 1 mg varenicline did not produce any significant positive or negative subjective responses in smokers. In non-smokers, 1 mg varenicline produced an increase in some positive subjective effects, but this was accompanied by an increase in negative adverse effects, especially nausea. A single oral dose of 3 mg varenicline uniformly produced unpleasant subjective responses in both smokers and non-smokers. **Animals:** Studies in rodents have shown that varenicline produces behavioral responses similar to those produced by nicotine. In rats trained to discriminate nicotine from saline, varenicline produced full generalization to the nicotine cue. In self-administration studies, the degree to which varenicline substitutes for nicotine is dependent upon the requirement of the task. Rats trained to self-administer nicotine under easy conditions continued to self-administer varenicline to a degree comparable to that of nicotine, however in a more demanding task, rats self-administered varenicline to a lesser extent than nicotine. Varenicline pretreatment also reduced nicotine self-administration.

OVERDOSEAGE

In case of overdose, standard supportive measures should be instituted as required. Varenicline has been shown to be dialyzed in patients with end stage renal disease (see Full Prescribing Information, CLINICAL PHARMACOLOGY, Pharmacokinetics, Pharmacokinetics in Special Patient Populations), however, there is no experience in dialysis following overdose.

DOSAGE AND ADMINISTRATION

Usual Dosage for Adults Smoking cessation therapies are more likely to succeed for patients who are motivated to stop smoking and who are provided additional advice and support. Patients should be provided with appropriate educational materials and counseling to support the quit attempt. The patient should set a date to stop smoking. CHANTIX dosing should start one week before this date. CHANTIX should be taken after eating and with a full glass of water. The recommended dose of CHANTIX is 1 mg twice daily following a 1-week titration as follows:

Days 1-3:	0.5 mg once daily
Days 4-7:	0.5 mg twice daily
Days 8-End of treatment:	1 mg twice daily

Patients who cannot tolerate adverse effects of CHANTIX may have the dose lowered temporarily or permanently. Patients should be treated with CHANTIX for 12 weeks. For patients who have successfully stopped smoking at the end of 12 weeks, an additional course of 12 weeks treatment with CHANTIX is recommended to further increase the likelihood of long-term abstinence. Patients who do not succeed in stopping smoking during 12 weeks of initial therapy, or who relapse after treatment, should be encouraged to make another attempt once factors contributing to the failed attempt have been identified and addressed.

Special Populations

Patients with impaired renal function No dosage adjustment is necessary for patients with mild to moderate renal impairment. For patients with severe renal impairment, the recommended starting dose of CHANTIX is 0.5 mg once daily. Patients may then titrate as needed to a maximum dose of 0.5 mg twice a day. For patients with End-stage renal disease undergoing hemodialysis, a maximum dose of 0.5 mg once daily may be administered if tolerated well (See Full Prescribing Information, CLINICAL PHARMACOLOGY, Pharmacokinetics, Pharmacokinetics in Special Populations, Renal Impairment).

Dosing in elderly patients and patients with impaired hepatic function No dosage adjustment is necessary for patients with hepatic impairment. Because elderly patients are more likely to have decreased renal function, care should be taken in dose selection, and it may be useful to monitor renal function (See PRECAUTIONS, Geriatric Use).

Use in children Safety and effectiveness of CHANTIX in pediatric patients have not been established; therefore, CHANTIX is not recommended for use in patients under 18 years of age.

Rx only

May 2007, Version 2.0



Continued from previous page

flammation, according to the report.

In terms of treating the disease, dietary therapy in particular should be considered in all children diagnosed with the condition, as there is strong circumstantial evidence that food allergens contribute to the pathogenesis of the disease in children. In fact, "the removal of food antigens has clearly been demonstrated to successfully treat both the symptoms and the underlying histopathology in the majority of patients with EE," the authors wrote. Toward this end, allergy testing and clinical history can help guide specific food elimination,

they stated, adding that consultation with a registered dietitian is advisable to ensure that proper nutrition is maintained.

Corticosteroids can effectively resolve acute clinicopathologic features of EE, but the disease typically recurs when the steroids are stopped. And while systemic corticosteroids have a role in emergent cases, including dysphagia requiring hospitalization, dehydration because of swallowing difficulties, and weight loss, the potential for significant toxicity over time should preclude their long-term use, the authors stated. Topical corticosteroids have also shown some efficacy and are associated with fewer side effects, they noted.

Although gastric acid is not thought to be the primary mediator of EE, acid suppression may be considered as cotherapy in patients with established disease who have symptoms secondary to GERD.

For patients who present with symptomatic esophageal narrowing secondary to fixed strictures causing food impaction, esophageal dilatation may be a useful treatment option, the authors wrote. To minimize the risk of mucosal tearing and perforation, however, "a diagnostic endoscopy with biopsy followed by medical or dietary therapy for EE should be attempted prior to performing esophageal dilatation," they stressed. And the esophagus should be in-

spected, either radiographically or by gentle endoscopic examination, after dilation to assess for laceration injury before performing larger caliber dilation.

Biologic agents that specifically target eosinophil activity may present a unique treatment opportunity for some patients with EE; however, they cannot yet be recommended for routine use given the lack of clinical trial data to date, according to the authors.

"The motivating factor for treating all patients should be symptom relief and prevention of complications of esophageal strictures and long-segment narrowing," said Dr. Furuta. ■

Hypnotherapy Beats Standard IBS Care for Kids

WASHINGTON — Children and adolescents with functional abdominal pain or irritable bowel syndrome who were treated with hypnotherapy were cured of their illness in significantly greater numbers than were children given standard medical treatment in a randomized, controlled trial presented at the annual Digestive Disease Week.

Dr. Arine M. Vlioger of St. Antonius Hospital, Nieuwegein, the Netherlands and her colleagues randomly assigned 53 patients (mean age 13 years) with functional abdominal pain (FAP) or irritable bowel syndrome (IBS) to either hypnotherapy or standard medical therapy (SMT).

Hypnotherapy consisted of six half-hour sessions based on the Manchester protocol of gut-directed hypnotherapy, conducted over 3 months (27 patients). The hypnotherapy sessions started with relaxation and abdominal breathing exercises. Other sessions dealt with control of gut function, pain control, and thinking relaxing thoughts. The children in this arm were asked to practice the techniques twice daily. SMT comprised pain medication and avoidance of pain triggers, plus six half-hour sessions of supportive therapy (25 patients); 1 patient did not complete therapy.

Three-fourths of the patients were female, and the mean duration of the abdominal complaints was 3.4 years.

The investigators found that immediately after therapy, 59% of patients given hypnotherapy were cured (defined as having a greater than 80% improvement in pain scores), compared with 12% of patients given SMT. At 1 year, the difference remained, with 85% and 25% classified as cured, respectively.

The proportions of patients who reported no effect of treatment (defined as less than 30% improvement in pain scores) were 56% of the SMT group and 15% of the hypnosis group after therapy; at 1 year, the figures were 46% for SMT patients and 4% for those given hypnotherapy.

Hypnotherapy has been used successfully in adults with IBS, and "the quality of life in these children [pretreatment] is comparable to [that of] those with Crohn's disease or ulcerative colitis," Dr. Vlioger said at a press conference.

—John R. Bell

For the treatment of hypertension and the reduction of cardiovascular (CV) events

YOUR REMOTE CONTROL TO REDUCE CV RISK

Blood pressure control as well as wide-ranging CV protection for high-risk patients aged ≥ 55 years



ALTACE[®]
(ramipril) capsules
Take control of CV protection

ALTACE[®] is indicated for the treatment of hypertension. It may be used alone or in combination with thiazide diuretics.

ALTACE[®] is indicated in patients 55 years or older at high risk of developing a major cardiovascular event, either because of a history of coronary artery disease, stroke, or peripheral vascular disease or because of diabetes that is accompanied by at least one other cardiovascular risk factor (hypertension, elevated total cholesterol levels, low HDL levels, cigarette smoking, or documented microalbuminuria), to reduce the risk of stroke, myocardial infarction, or death from cardiovascular causes. ALTACE[®] can be used in addition to other needed treatments (such as antihypertensive, antiplatelet, or lipid-lowering therapies).

Important Safety Information

When used in pregnancy during the second and third trimesters, ACE inhibitors can cause injury and even death to the developing fetus. When pregnancy is detected, ALTACE[®] should be discontinued as soon as possible.

Common adverse events associated with ALTACE[®] include persistent dry cough, dizziness, and symptomatic hypotension. Hypoglycemia has been reported rarely in concomitant therapy with oral hypoglycemics or insulin. Rare cases of angioedema, including intestinal angioedema, have been reported. ALTACE[®] is contraindicated in patients who are hypersensitive to the product or have a history of angioedema related to previous treatment with an ACE inhibitor.

Please see adjacent brief summary of Prescribing Information.



www.kingpharm.com www.altace.com

ALTACE is a registered trademark of King Pharmaceuticals Research and Development, Inc., a wholly owned subsidiary of King Pharmaceuticals[®], Inc.
Copyright © 2007 King Pharmaceuticals[®], Inc. All rights reserved.
ALT4465 03/2007